Back HIV/AIDS

HIV / AIDS

ICAAC 2014: New Drug Isavuconazole Is Effective Against Opportunistic Fungal Infections

A new antifungal drug, isavuconazole, matched the efficacy of voriconazole for treatment of invasive fungal infections in cancer patients with compromised immunity, but with fewer side effects, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.Isavuconazole was shown to be effective against various fungal infections that act as opportunistic illnesses in people with HIV/AIDS, including Aspergillus, Candida, and Cryptococcus.

alt

NIH Awards Grant for Vaginal Ring for HIV Prevention

The National Institutes of Health has awarded a $20 million grant to a consortium that will seek to develop an intravaginal ring that delivers antiretroviral drugs for prevention of HIV infection, the participating research institutions recently announced. The collaboration will test various combinations of antiretrovirals to determine which are most effective when delivered together for pre-exposure prophylaxis, or PrEP.

alt

Coverage of the Interscience Conference on Antimicrobial Agents and Chemotherapy

HIVandHepatitis.com coverage of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), September 5-9, in Washington, DC.

Conference highlights include experimental antiretroviral therapies for HIV, interferon-free treatment for hepatitis C, and news about other infectious diseases including tuberculosis, HPV, influenza, and Ebola virus.

Full listing of coverage by topic

ICAAC 2014 website

9/8/14

alt

ICAAC 2014: NRTI BMS-986001 Safe and Effective, but Associated with Resistance

BMS-986001, an experimental HIV nucleoside reverse transcriptase inhibitor, was shown to be as effective as tenofovir with less bone loss, but more people who took it developed resistance, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC. Bristol-Myers Squibb has announced it will end its development of the drug.

alt

ICAAC 2014: New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, according to a study presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

ICAAC 2014: PK Study Shows Feasibility of Long-acting Integrase Inhibitor Cabotegravir

A pharmacokinetic (PK) analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC, confirmed that the long-acting HIV integrase inhibitor cabotegravir (formerly GSK1265744) reaches adequate target levels in the blood, setting the stage for efficacy trials for HIV treatment and pre-exposure prophylaxis (PrEP).

alt

ICAAC 2014: Sangamo Provides Update on Gene Therapy to Protect T-cells From HIV

Several people with HIV whose CD4 T-cells were modified to make them resistant to viral entry have maintain low-level viral load after interrupting antiretroviral therapy (ART), with 1 individual having HIV RNA <1000 copies/mL for more than a year, according to a presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt